ADG126 + Pembrolizumab (KEYTRUDA®) + Standard of Care (Trifluridine/Tipiracil-Bevacizumab) + Standard of care (Fruquintinib)
Phase 1/2Recruiting 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced/Metastatic Solid Tumors
Conditions
Advanced/Metastatic Solid Tumors
Trial Timeline
Jun 15, 2022 → Apr 30, 2027
NCT ID
NCT05405595About ADG126 + Pembrolizumab (KEYTRUDA®) + Standard of Care (Trifluridine/Tipiracil-Bevacizumab) + Standard of care (Fruquintinib)
ADG126 + Pembrolizumab (KEYTRUDA®) + Standard of Care (Trifluridine/Tipiracil-Bevacizumab) + Standard of care (Fruquintinib) is a phase 1/2 stage product being developed by Merck for Advanced/Metastatic Solid Tumors. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05405595. Target conditions include Advanced/Metastatic Solid Tumors.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05405595 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Advanced/Metastatic Solid Tumors